Ástralía - enska - Department of Health (Therapeutic Goods Administration)

boehringer ingelheim pty ltd - linagliptin, quantity: 5 mg - tablet, film coated - excipient ingredients: mannitol; pregelatinised maize starch; maize starch; copovidone; magnesium stearate; titanium dioxide; hypromellose; purified talc; macrogol 6000; iron oxide red - trajenta is indicated in adult patients with type 2 diabetes mellitus to improve glycaemic control in conjunction with diet and exercise,,- as monotherapy when metformin and sulfonylureas are not tolerated, or are contraindicated, or,- as add on to metformin, sulfonylureas or metformin plus sulfonylureas, or to insulin (with or without metformin) or,- as add on to metformin plus sglt2 inhibitors.

Ísrael - enska - Ministry of Health

boehringer ingelheim israel ltd. - linagliptin - film coated tablets - linagliptin 5 mg - linagliptin - linagliptin - as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. trajenta should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis, as it would not be effective in these settings. trajenta has not been studied in patients with a history of pancreatitis. it is unknown whether patients with a history of pancreatitis are at an increased risk for the development of pancreatitis while using trajenta.

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

novo nordisk pharmaceuticals pty ltd - liraglutide, quantity: 6 mg/ml - injection, solution - excipient ingredients: phenol; hydrochloric acid; water for injections; propylene glycol; dibasic sodium phosphate dihydrate; sodium hydroxide - saxenda is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adult patients with an initial body mass index (bmi) of:,- greater than or equal to 30 kg/m2 (obese) or,- greater than or equal to 27 kg/m2 to <30 kg/m2 (overweight) in the presence of at least one weight related comorbidity, such as dysglycaemia (pre-diabetes and type 2 diabetes mellitus), hypertension, dyslipidaemia, or obstructive sleep apnoea.,treatment with saxenda should be discontinued after 12 weeks on the 3.0 mg/day dose if a patient has not lost at least 5% of their initial body weight.

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

novo nordisk pharmaceuticals pty ltd - liraglutide, quantity: 6 mg/ml - injection, solution - excipient ingredients: phenol; hydrochloric acid; water for injections; propylene glycol; dibasic sodium phosphate dihydrate; sodium hydroxide - glycaemic control,victoza is indicated as an adjunct to diet and exercise for treatment of adults with type 2 diabetes mellitus to achieve glycaemic control:,- as monotherapy when metformin is contraindicated or is not tolerated,- in combination with other glucose lowering medicines.,prevention of cardiovascular events,in patients where victoza is indicated to improve glycaemic control, victoza is indicated to reduce the risk of cardiovascular events in those at high cardiovascular risk, as an adjunct to standard of care therapy (see clinical trials).

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

boehringer ingelheim pty ltd - empagliflozin, quantity: 10 mg; linagliptin, quantity: 5 mg - tablet, film coated - excipient ingredients: iron oxide yellow; macrogol 6000; hypromellose; crospovidone; maize starch; titanium dioxide; mannitol; purified talc; pregelatinised maize starch; copovidone; magnesium stearate - glyxambi tablets are indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus when treatment with both empagliflozin and linagliptin is appropriate (see sections 4.2 dose and method of administration and 5.1 pharmacodynamic properties ? clinical trials).

Malta - enska - Malta Medicines Authority

pharos – pharmaceutical oriented services limited lesvou str. (end), thesi loggos, industrial zone, 144 52 metamorfossi attikis,, greece - film-coated tablet - linagliptin 2.5 mg metformin hydrochloride 500 mg - drugs used in diabetes

Malta - enska - Malta Medicines Authority

pharos – pharmaceutical oriented services limited lesvou str. (end), thesi loggos, industrial zone, 144 52 metamorfossi attikis,, greece - film-coated tablet - linagliptin 2.5 mg metformin hydrochloride 850 mg - drugs used in diabetes

Malta - enska - Malta Medicines Authority

pharos – pharmaceutical oriented services limited lesvou str. (end), thesi loggos, industrial zone, 144 52 metamorfossi attikis,, greece - film-coated tablet - linagliptin 2.5 mg metformin hydrochloride 1000 mg - drugs used in diabetes

Ísrael - enska - Ministry of Health

novo nordisk ltd., israel - liraglutide - solution for injection - liraglutide 6.0 mg/ml - liraglutide - liraglutide - victoza is indicated for:• treatment of adults, adolescents and children aged 10 years and above with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise:1. as monotherapy when metformin is considered inappropriate due to intolerance or contraindications2. in addition to other medicinal products for the treatment of diabetes.• to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with type 2 diabetes mellitus and established cardiovascular disease

Malta - enska - Malta Medicines Authority

clonmel healthcare limited waterford road, clonmel, co. tipperary e91 d768, ireland - film-coated tablet - linagliptin 2.5 mg metformin hydrochloride 500 mg - drugs used in diabetes